Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype

  • STATUS
    Recruiting
  • participants needed
    44
  • sponsor
    Memorial Sloan Kettering Cancer Center
Updated on 5 February 2023
cancer
karnofsky performance status
MRI
prothrombin
neutrophil count
blood transfusion
astrocytoma
malignant glioma
anaplastic astrocytoma
astrocytoma, anaplastic
recurrent malignant glioma
recurrent tumor

Summary

The purpose of this study is to test if the study drug called pembrolizumab could control the growth or shrink the cancer but it could also cause side effects. Researchers hope to learn if the study drug will shrink the cancer by half, or prevent it from growing for at least 6 months. Pembrolizumab is an antibody that targets the immune system and activates it to stop cancer growth and/or kill cancer cells.

Details
Condition Glioma, Recurrent Malignant Glioma
Treatment Pembrolizumab
Clinical Study IdentifierNCT02658279
SponsorMemorial Sloan Kettering Cancer Center
Last Modified on5 February 2023

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note